IN2015KN00571A - - Google Patents

Info

Publication number
IN2015KN00571A
IN2015KN00571A IN571KON2015A IN2015KN00571A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A IN 571KON2015 A IN571KON2015 A IN 571KON2015A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A
Authority
IN
India
Prior art keywords
vascular
present disclosure
ntprocnp
finding
subject
Prior art date
Application number
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of IN2015KN00571A publication Critical patent/IN2015KN00571A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present disclosure relates to methods for the prognosis and/or diagnosis of vascular related disorders in a subject and in particular pregnancy related vascular disorders. The present disclosure is based on the finding that a positive correlation exists between positive prediction of a vascular disorder event in a subject and the concentration of the circulating marker NTproCNP (also referred to as NT CNP) in humans and animals. In addition, the present disclosure is based on the finding that there is also a positive correlation between the occurrence of a vascular related adverse event during pregnancy and the concentration of the circulating marker NTproCNP in the maternal circulation.
IN571KON2015 2012-08-13 2013-08-13 IN2015KN00571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (1)

Publication Number Publication Date
IN2015KN00571A true IN2015KN00571A (en) 2015-07-17

Family

ID=50101335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN571KON2015 IN2015KN00571A (en) 2012-08-13 2013-08-13

Country Status (9)

Country Link
US (1) US10012656B2 (en)
EP (1) EP2883060B1 (en)
JP (1) JP6423788B2 (en)
CN (1) CN104937420B (en)
AU (1) AU2013303302B2 (en)
CA (1) CA2882116A1 (en)
IN (1) IN2015KN00571A (en)
SG (2) SG10201700872TA (en)
WO (1) WO2014027899A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
TWI776812B (en) * 2016-06-02 2022-09-11 荷蘭商菲林公司 Angiotensin-1-receptor antagonists
WO2018216580A1 (en) * 2017-05-22 2018-11-29 東ソー株式会社 Method for providing prognostic prediction information on basis of adrenomedullin concentration fluctuation and reagent therefor
WO2019199865A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in dried physiological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407580B (en) * 1999-08-20 2001-04-25 Biomedica Gmbh INDICATOR PEPTIDE FOR DIAGNOSIS AND / OR PREDICTION OF CARDIOVASCULAR AND / OR ENDOTHELIAL DISEASES, ANTIBODY COMPOSITION AND IMMUNOASSAY
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
US7919255B2 (en) * 2003-06-17 2011-04-05 Otago Innovation Limited Assessment of skeletal growth using measurements of NT-CNP peptides
DE10338733A1 (en) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusion polypeptides and their use for antivascular tumor therapy
WO2008042855A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
RU2013102112A (en) * 2010-06-18 2014-07-27 Сезанн С.А.С. MARKERS FOR FORECASTING AND EVALUATING THE RISK OF DEVELOPMENT DUE TO PREGNANCY HYPERTENSION AND PREECLAMPSIA
EP3088416B1 (en) 2011-12-23 2019-02-27 Mayo Foundation for Medical Education and Research Assessing renal structural alterations and outcomes
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Also Published As

Publication number Publication date
WO2014027899A1 (en) 2014-02-20
JP6423788B2 (en) 2018-11-14
AU2013303302A1 (en) 2015-03-12
US10012656B2 (en) 2018-07-03
EP2883060A1 (en) 2015-06-17
SG11201501145SA (en) 2015-04-29
EP2883060B1 (en) 2018-03-21
CA2882116A1 (en) 2014-02-20
CN104937420B (en) 2018-07-03
US20150241451A1 (en) 2015-08-27
AU2013303302B2 (en) 2017-10-12
CN104937420A (en) 2015-09-23
EP2883060A4 (en) 2016-06-29
SG10201700872TA (en) 2017-04-27
JP2015526725A (en) 2015-09-10

Similar Documents

Publication Publication Date Title
IN2015KN00571A (en)
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
BR112017011172A2 (en) interference attenuation for positioning reference signals
BR112015030293A2 (en) magnetic data compensation for autonomous subsea vehicle mapping inspections
BR112015009948A2 (en) activin-actria antagonists and uses for bone treatment and other disorders
BR112015017767A2 (en) system for detecting an individual's sleep stages, method for detecting an individual's sleep stages, and system configured for detecting an individual's sleep stages
WO2014133855A8 (en) Tuberculosis biomarkers and uses thereof
WO2012101511A3 (en) System, method and device for automatic and autonomous determination of hemodynamic and cardiac parameters using ultrasound
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
BR112018001260A2 (en) aqueous mixture, freeze-dried composition, and methods for immunizing a human subject and for preparing a composition.
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
BR112017009976A2 (en) hybrid dairy cattle and systems to maximize hybrid advantage
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
BR112015005369A2 (en) usp30 inhibitors and methods for their use
WO2013130953A3 (en) Autism-associated biomarkers and uses thereof
CA3010708A1 (en) Methods of administering hepcidin
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
MX2022010954A (en) Device for detecting misfolded proteins and methods of use therof.
MA40592A (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
MX2019002818A (en) Methods of detecting anti-leptin neutralizing antibodies.
WO2015085055A3 (en) Methods of treating or preventing pruritis by blocking natriuretic polypeptide b
FR2979346B1 (en) NANOCORPS ANTI-VCAM-1
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies